Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$7.99 - $11.02 $14,190 - $19,571
1,776 Added 12.42%
16,076 $148,000
Q4 2022

Feb 14, 2023

BUY
$7.55 - $11.96 $107,965 - $171,028
14,300 New
14,300 $126,000
Q3 2019

Nov 14, 2019

SELL
$23.83 - $36.44 $392,813 - $600,676
-16,484 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$32.75 - $40.35 $5.32 Million - $6.56 Million
-162,512 Reduced 90.79%
16,484 $592,000
Q1 2019

May 15, 2019

BUY
$35.47 - $54.55 $2.1 Million - $3.23 Million
59,260 Added 49.49%
178,996 $6.61 Million
Q4 2018

Feb 14, 2019

BUY
$38.35 - $50.39 $505,759 - $664,543
13,188 Added 12.38%
119,736 $5.16 Million
Q3 2018

Nov 14, 2018

BUY
$41.65 - $51.7 $3.56 Million - $4.42 Million
85,416 Added 404.2%
106,548 $5.03 Million
Q2 2018

Aug 14, 2018

BUY
$48.35 - $65.33 $1.02 Million - $1.38 Million
21,132 New
21,132 $1.05 Million

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $251M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.